Open access
Open access
Powered by Google Translator Translator

Vaccines

EULAR/PRES recommendations for vaccination of pediatric patients with autoimmune inflammatory rheumatic diseases.

24 Jun, 2022 | 11:17h | UTC

EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021 – Annals of Rheumatic Diseases

 

Cohort Study: Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA.

22 Jun, 2022 | 12:07h | UTC

Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases – The Lancet

Commentaries:

COVID-19 mRNA vaccination and myocarditis or pericarditis – The Lancet

Myocarditis and Pericarditis After the COVID-19 mRNA Vaccination – American College of Cardiology

Related:

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents – JAMA Cardiology

Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals – UK Health Security Agency

Myocarditis following a third Pfizer vaccination dose in military recruits in Israel.

Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Comparing the Pfizer and Moderna Covid vaccines for young children.

22 Jun, 2022 | 12:02h | UTC

Comparing the Pfizer and Moderna Covid vaccines for young children – STAT

Related: FDA advisers OK COVID-19 vaccines for youngest kids – CIDRAP

 

WHO Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines.

20 Jun, 2022 | 10:42h | UTC

Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines – World Health Organization

See also: Interim statement on the composition of current COVID-19 vaccines – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

Test-negative, case–control study: Effects of previous infection and vaccination on symptomatic omicron infections.

17 Jun, 2022 | 11:44h | UTC

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections – New England Journal of Medicine

Commentary: Qatar Omicron-wave study shows slow decline of natural immunity, rapid decline of vaccine immunity – Weill Cornell Medicine

Related:

Hybrid immunity: a combination of vaccination and prior infection probably offers the best protection against COVID – The Conversation

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity – Environmental Research

Two new studies show vaccination provides additional protection after Covid-19 infection.

 

Commentary on Twitter

 

FDA advisers OK COVID-19 vaccines for youngest kids.

17 Jun, 2022 | 11:43h | UTC

FDA advisers OK COVID-19 vaccines for youngest kids – CIDRAP

See also: FDA advisers endorse 1st COVID-19 shots for kids under 5 – Associated Press

 

Comparative safety of BNT162b2 and mRNA-1273 vaccines in a nationwide cohort of US veterans.

14 Jun, 2022 | 11:08h | UTC

Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans – JAMA Internal Medicine

Commentary: Few differences in safety profiles of Moderna, Pfizer COVID-19 vaccines – Harvard T.H. Chan School of Public Health

 

Commentary on Twitter

 

Maternal vaccination: a review of current evidence and recommendations.

3 Jun, 2022 | 11:40h | UTC

Maternal vaccination: a review of current evidence and recommendations – American Journal of Obstetrics & Gynecology

 

Commentary on Twitter

 

Network Meta-Analysis: Effectiveness of heterologous and homologous covid-19 vaccine regimens.

1 Jun, 2022 | 12:00h | UTC

Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis – The BMJ

News Release: Three doses of the same or mixed covid jabs work equally well against infections – BMJ

Commentary: Three jabs best for preventing Covid infections, global analysis finds – The Guardian

 

Analysis/Opinion: The unintended consequences of COVID-19 vaccine policy: “why mandates, passports and restrictions may cause more harm than good”.

30 May, 2022 | 11:46h | UTC

The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good – BMJ Global Health

 

Commentary on Twitter (thread – click for more)

 

Covid-19: Vaccine effectiveness wanes more rapidly for cancer patients, study finds.

27 May, 2022 | 12:04h | UTC

Commentary: Covid-19: Vaccine effectiveness wanes more rapidly for cancer patients, study finds – The BMJ

Original Study: Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study – The Lancet Oncology

Editorial: COVID-19 vaccine effectiveness in patients with cancer: remaining vulnerabilities and uncertainties – The Lancet Oncology

 

Study Commentary: Long COVID risk falls only slightly after vaccination, huge study shows.

26 May, 2022 | 11:25h | UTC

Commentary: Long COVID risk falls only slightly after vaccination, huge study shows – Nature

Original Study: Long COVID after breakthrough SARS-CoV-2 infection – Nature Medicine

 

Commentary from the author on Twitter (thread – click for more)

 

Cohort Study: Protection and waning of natural and hybrid immunity to SARS-CoV-2.

26 May, 2022 | 11:07h | UTC

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine

Editorial: Audio Interview: Waning Immunity against Covid-19

 

Commentary on Twitter

 

Test-negative, case–control study: effectiveness of homologous and heterologous Covid-19 boosters against Omicron.

26 May, 2022 | 10:59h | UTC

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron – New England Journal of Medicine

 

Effectiveness of CoronaVac in children 3 to 5 years during the SARS-CoV-2 Omicron outbreak in Chile.

25 May, 2022 | 11:42h | UTC

Effectiveness of CoronaVac in children 3 to 5 years during the SARS-CoV-2 Omicron outbreak in Chile – Nature Medicine

 

Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study.

25 May, 2022 | 11:34h | UTC

Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study – The BMJ

Related recommendations:

Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO – The BMJ

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

 

RCT: Safety and immunogenicity of heterologous boost immunization with an orally administered aerosolized Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults.

23 May, 2022 | 01:54h | UTC

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial – The Lancet Respiratory Medicine

 

Commentary on Twitter

 

WHO validates 11th vaccine for COVID-19.

20 May, 2022 | 11:16h | UTC

WHO validates 11th vaccine for COVID-19 – World Health Organization

 

Commentary on Twitter

 

Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO.

20 May, 2022 | 11:08h | UTC

Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO – The BMJ

Original Statement: Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19 – World Health Organization

Related recommendations:

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

 

RCT: Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age.

12 May, 2022 | 10:22h | UTC

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age – New England Journal of Medicine

 

Commentary on Twitter

 

Phase 2 RCT: A fourth dose of an mRNA Covid-19 vaccine increases cellular and humoral immunity against SARS-CoV-2.

11 May, 2022 | 11:14h | UTC

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial – The Lancet Infectious Diseases

Commentaries:

What a second booster dose of mRNA COVID-19 vaccines tells us – The Lancet Infectious Diseases

Covid: Fourth-dose jab trial shows good boost – BBC

 

Commentary on Twitter (thread – click for more)

 

M-A: Interventions to improve immunization coverage among children and adolescents.

11 May, 2022 | 10:45h | UTC

Interventions to Improve Immunization Coverage Among Children and Adolescents: A Meta-analysis – Pediatrics

 

Kids get limited COVID protection from world’s most popular vaccines – “First analyses of two Chinese-made vaccines in young children show that the shots do provide 60–65% effectiveness against hospitalization”.

10 May, 2022 | 11:04h | UTC

Kids get limited COVID protection from world’s most popular vaccines – Nature

 

Studies show promise for 2 new COVID vaccine platforms.

9 May, 2022 | 02:12h | UTC

Commentary: Studies show promise for 2 new COVID vaccine platforms – CIDRAP

Study 1: Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine – New England Journal of Medicine

Study 2: Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults – New England Journal of Medicine

Editorial: Does the World Still Need New Covid-19 Vaccines?

 

Commentaries on Twitter

 

M-A of randomized trials: association of influenza vaccination with cardiovascular risk.

3 May, 2022 | 10:58h | UTC

Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis – JAMA Network Open

 

Commentary on Twitter

 

Stay Updated in Your Specialty

No spam, just news.